Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Kenjiro Kamezaki Last modified date:2019.07.26

Lecturer / Biosystemic sciences, Kyushu University Graduate School of Medicine / Kyushu University Hospital

1. Shuichiro Takashima, Tetsuya Eto, Motoaki Shiratsuchi, Michihiro Hidaka, Yasuo Mori, Koji Kato, Kenjiro Kamezaki, Seido Oku, Hideho Henzan, Ken Takase, Takamitsu Matsushima, Katsuto Takenaka, Hiromi Iwasaki, Toshihiro Miyamoto, Koichi Akashi, Takanori Teshima, The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease
The experience of the Fukuoka Blood and Marrow Transplantation (BMT) Group, Internal Medicine, 10.2169/internalmedicine.53.1858, 53, 12, 1315-1320, 2014.01, Objective: We examined the therapeutic strategies for treating mild gastrointestinal (GI) graft-versus-host disease (GVHD) using oral beclomethasone dipropionate (BDP) in 15 Japanese patients based on the donor source. The primary objective was to determine the efficacy and toxicity of oral BDP combined with/without low-dose prednisone (PSL). Methods: Oral BDP was administered with 1 mg/kg/d of PSL in patients undergoing bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT; n=11), and the dose of PSL was tapered off after 22 days. Oral BDP alone was administered in patients undergoing cord blood stem cell transplantation (CBSCT; n=4). The primary endpoint was the rate of treatment success on day 49, as measured according to the improvement or complete resolution of GI symptoms without additional treatment. The secondary endpoints included treatment-related toxicity according to the National Cancer Institute Common Toxicity Criteria version 3.0, the rate of treatment discontinuation due to toxicity, the rate of relapse of acute GVHD by day 100 and the incidence of bacterial, fungal or viral infection, including cytomegalovirus (CMV) antigenemia. Results: Treatment success was achieved in seven of the 11 (64%) patients undergoing BMT or PBSCT and in all four patients (100%) undergoing CBSCT. Subsequent adverse events included herpes zoster infection, catheter-associated sepsis and CMV enteritis; all affected patients responded well to treatment. Conclusion: The use of a risk-stratified treatment strategy with oral BDP depending on the stem cell source is effective in patients with mild GI-GVHD..
2. Mariko Minami, Takahiro Shima, Koji Kato, Hidetaka Yamamoto, Kenji Tsuchihashi, Seido Oku, Tomonori Shimokawa, Taro Tochigi, Goichi Yoshimoto, Kenjiro Kamezaki, Katsuto Takenaka, Hiromi Iwasaki, Yoshinao Oda, Toshihiro Miyamoto, Koichi Akashi, Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy, International Journal of Hematology, 10.1007/s12185-015-1778-0, 102, 2, 244-248, 2015.08, Langerhans cell histiocytosis (LCH) is a rare disease in adults. The treatment strategy for this condition remains controversial. Intensified systemic chemotherapy is required in pediatric patients with the multiple system form of LCH (MS-LCH) for aggressive forms of the disease. Recent clinical trials have shown that intensified chemotherapy for pediatric patients diagnosed with MS-LCH results in improved outcomes. However, whether the feasibility and efficacy of an intensified systemic chemotherapy regimen are also beneficial for adult patients with MS-LCH remains unclear. Here, we report two cases of adult MS-LCH that were successfully treated with an intensified treatment protocol as used in pediatric patients. One patient fully completed the protocol, and has since maintained a complete response (CR) for 2 years following completion of the treatment. The other patient also achieved CR after induction therapy, and is now undergoing maintenance therapy in an outpatient clinic. The cases presented in this study suggest that intensified systemic chemotherapy as used for pediatric patients with MS-LCH is well tolerated and effective for adult patients as well..
3. Yasuo Mori, Goichi Yoshimoto, Ruriko Nishida, Takeshi Sugio, Kohta Miyawaki, Takahiro Shima, Yoji Nagasaki, Noriko Miyake, Yukiko Harada, Yuya Kunisaki, Kenjiro Kamezaki, Akihiko Numata, Koji Kato, Motoaki Shiratsuchi, Takahiro Maeda, Katsuto Takenaka, Hiromi Iwasaki, Nobuyuki Shimono, Koichi Akashi, Toshihiro Miyamoto, Gastrointestinal Graft-versus-Host Disease Is a Risk Factor for Postengraftment Bloodstream Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients, Biology of Blood and Marrow Transplantation, 10.1016/j.bbmt.2018.06.002, 24, 11, 2302-2309, 2018.11, Bloodstream infection (BSI) is a well-known cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. Here, we conducted a retrospective study to assess the morbidity, etiology, risk factors, and outcomes of BSI in the postengraftment period (PE-BSI) after allo-HSCT. Forty-three of 316 patients (13.6%) developed 57 PE-BSI episodes, in which 62 pathogens were isolated: Gram-positive bacteria, gram-negative bacteria, and fungi, respectively, accounted for 54.8%, 35.5%, and 9.7% of the isolates. Multivariate analysis revealed methylprednisolone use for graft-versus-host disease (GVHD) prophylaxis (odds ratio [OR], 6.49; 95% confidence interval [CI], 1.49 to 28.2; P =.013) and acute gastrointestinal GVHD (GI-GVHD) (OR, 8.82; 95% CI, 3.99 to 19.5; P <.0001) as risk factors for developing PE-BSI. This finding suggested that GI-GVHD increases the risk of bacterial translocation and subsequent septicemia. Moreover, among patients with GI-GVHD, insufficient response to corticosteroids, presumably related to an intestinal dysbiosis, significantly correlated with this complication. Patients with PE-BSI presented worse outcome compared with those without (3-year overall survival, 47.0% versus 18.6%; P <.001). Close microbiologic monitoring for BSIs and minimizing intestinal dysbiosis may be crucial to break the vicious cycle between GI-GVHD and bacteremia and to improve transplant outcomes especially in patients who require additional immunosuppressants..
4. Goichi Yoshimoto, Yasuo Mori, Koji Kato, Takahiro Shima, Kohta Miyawaki, Yoshikane Kikushige, Kenjiro Kamezaki, Akihiko Numata, Takahiro Maeda, Katsuto Takenaka, Hiromi Iwasaki, Takanori Teshima, Koichi Akashi, Toshihiro Miyamoto, Human Herpes Virus-6–Associated Encephalitis/Myelitis Mimicking Calcineurin Inhibitor–Induced Pain Syndrome in Allogeneic Stem Cell Transplantation Recipients, Biology of Blood and Marrow Transplantation, 10.1016/j.bbmt.2018.07.017, 24, 12, 2540-2548, 2018.12, Human herpes virus-6 (HHV6)-associated myelitis and calcineurin inhibitor–induced pain syndrome (CIPS) are serious complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Because these 2 complications cause similar sensory nerve–related symptoms, such as paresthesia, pruritus, and severe pain occurring around the engraftment, it can be difficult to differentially diagnose the 2 conditions. We retrospectively analyzed 435 recipients to distinguish clinical symptoms of these 2 complications. Twenty-four patients (5.5%) developed HHV6-associated encephalitis/myelitis; of these, 11 (2.5%) presented only with myelitis-related symptoms (HHV6-associated myelitis), which was confirmed by the detection of HHV6 DNA, and 8 (1.8%) had CIPS, with undetected HHV6 DNA. All patients with HHV6-associated myelitis or CIPS exhibited similar sensory nerve–related symptoms. Diagnostic images did not provide definite evidence specific for each disease. Symptoms of all patients with CIPS improved after switching to another immunosuppressant. Overall survival rate at 2 years for patients with HHV6-associated encephalitis/myelitis was significantly lower than that of CIPS (13.1% versus 29.2%; P =.049) or that of patients without HHV6-associated encephalitis/myelitis or CIPS (42.4%; P =.036), whereas there was no significant difference among the latter 2 groups (P =.889). The development of HHV6-associated encephalitis/myelitis but not CIPS was significantly associated with poor prognosis. Thus, transplant physicians should be aware that sensory nerve–related symptoms indicate early manifestations that might be correlated with reactivation of HHV6 or CIPS. Therefore, identification of HHV6 DNA is crucial for making a differential diagnosis and immediately starting appropriate treatments for each complication..
5. Takatoshi Aoki, Tomohiko Kamimura, Shuro Yoshida, Yasuo Mori, Masanori Kadowaki, Kentaro Kohno, Daisuke Ishihara, Shingo Urata, Takeshi Sugio, Kenjiro Kamezaki, Koji Kato, Yoshikiyo Ito, Tetsuya Eto, Koichi Akashi, Toshihiro Miyamoto, Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, 10.1016/j.bbmt.2019.04.006, 2019.01, Vaccination against vaccine-preventable diseases (VPDs) is highly recommended for hematopoietic stem cell transplantation (HSCT) recipients by several guidelines; however, the safety and seropositivity after live attenuated vaccines remain unclear in adult HSCT recipients. We analyzed titers of antibodies against measles, rubella, mumps, and varicella zoster virus (VZV) from Japanese adult patients who underwent allogeneic HSCT (allo-HSCT) (n = 74), autologous HSCT (auto-HSCT) (n = 39), or chemotherapy (n = 93). The seropositive rates for measles, rubella, mumps, and VZV in allo-HSCT recipients were 20.2%, 36.4%, 5.4%, and 55.4%, respectively. These rates were equivalent to those in auto-HSCT recipients but were significantly lower than those in patients receiving chemotherapy. Antibody titers tended to gradually decrease with time. Twenty-nine allo-HSCT recipients and 8 auto-HSCT recipients received live attenuated vaccines against VPDs for which they tested seronegative. The titers of antibodies against measles, rubella, and mumps significantly increased after 2 shots of vaccine, and the seropositive rate increased up to 19%, 30%, and 27%, respectively. Three patients (8.1%) experienced mild adverse events, which resolved promptly, indicating safe administration of the live attenuated vaccines. In multivariate analysis, history of chronic graft-versus-host disease was significantly associated with high seropositivity for measles as well as high seroconversion rate for measles after vaccination. Live attenuated vaccines against VPDs were safely administered in seronegative adult HSCT recipients. A further observational study is crucial to evaluate the efficacy of vaccination in seronegative HSCT patients..
6. Kisho Ohtani, Takeo Fujino, Tomomi Ide, Kouta Funakoshi, Ichirou Sakamoto, Hiasa Ken-Ichi, Taiki Higo, Kenjiro Kamezaki, Koichi Akashi, Hiroyuki Tsutsui, Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity, Clinical Research in Cardiology, 10.1007/s00392-018-1386-0, 108, 6, 600-611, 2019.06, Background: Left ventricular (LV) dysfunction due to anthracycline-induced cardiotoxicity (AIC) has been believed to be irreversible. However, this has not been confirmed and standard medical treatment for heart failure (HF) including renin–angiotensin inhibitors and β-blockers may lead to its recovery. Methods and results: We thus retrospectively studied 350 cancer patients receiving anthracycline-based chemotherapy from 2001 to 2015 in our institution. Fifty-two patients (14.9%) developed AIC with a decrease in LV ejection fraction (LVEF) of 24.1% at a median time of 6 months [interquartile range (IQR) 4–22 months] after anthracycline therapy. By multivariate analysis, AIC was independently associated with cardiac comorbidities including ischemic heart disease, valvular heart disease, arrhythmia, and cardiomyopathy [odds ratio (OR) 6.00; 95% confidence interval (CI) 2.27–15.84, P = 0.00044), lower baseline LVEF (OR per 1% 1.09; 95% CI 1.04–1.14, P = 0.00034). During the median follow-up of 3.2 years, LV systolic dysfunction recovered among 33 patients (67.3%) with a median time of 4 months (IQR 2–6 months), which was independently associated with the introduction of standard medical treatment for HF (OR 9.39; 95% CI 2.27–52.9, P = 0.0014) by multivariate analysis. Conclusion: Early initiation of standard medical treatment for HF may lead to LV functional recovery in AIC..
7. Teppei Sakoda, Yoko Kanamitsu, Yasuo Mori, Kensuke Sasaki, Etsuko Yonemitsu, Konosuke Nagae, Goichi Yoshimoto, Kenjiro Kamezaki, Koji Kato, Katsuto Takenaka, Toshihiro Miyamoto, Masutaka Furue, Hiromi Iwasaki, Koichi Akashi, Recurrent subcutaneous sweet’s disease in a myelofibrosis patient treated with ruxolitinib before allogeneic stem cell transplantation, Internal Medicine, 10.2169/internalmedicine.8491-16, 56, 18, 2481-2485, 2017.01, Allogeneic hematopoietic stem cell transplantation (allo-SCT) has a curative potential for myelofibrosis (MF) patients; however, its association with a high therapy-related mortality (TRM) remains a big obstacle that needs to be overcome. Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as a bridging therapy until allo-SCT can be performed to reduce TRM. We herein report a RUXO-treated MF patient who developed recurrent subcutaneous Sweet’s disease (SSD) that was successfully treated by the administration of systemic glucocorticoids. We performed allo-SCT as previously scheduled, resulting in a good clinical course without deterioration of SSD. RUXO administration, as well as MF itself, might therefore sometimes cause this rare non-infectious event..
8. Mayako Uchida, Yasuo Mori, Tsutomu Nakamura, Koji Kato, Kenjiro Kamezaki, Katsuto Takenaka, Motoaki Shiratsuchi, Kaori Kadoyama, Toshihiro Miyamoto, Koichi Akashi, Comparison between antiemetic effects of palonosetron and granisetron on chemotherapy-induced nausea and vomiting in Japanese patients treated with R-CHOP, Biological and Pharmaceutical Bulletin, 10.1248/bpb.b17-00318, 40, 9, 1499-1505, 2017.01, In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron. A total of 74 patients with non-Hodgkin lymphoma were included in this study (April 2007 to December 2015). Palonosetron (0.75 mg) or granisetron (3 mg) was intravenously administered before R-CHOP therapy. The proportions of patients with complete response (CR) during the overall (0-120 h after the start of R-CHOP therapy), acute (0-24 h) and delayed (24-120 h) phases were evaluated. CR was defined as no vomiting and no use of antiemetic rescue medication. A total of 32 and 42 patients were treated with palonosetron and granisetron, respectively. The CR rate in the palonosetron group was significantly higher than that in the granisetron group during the delayed phase (90.6 and 61.9%, respectively; p=0.007). Logistic regression analysis showed that use of palonosetron improved the CR rate during the delayed phase, compared to use of granisetron. Female sex, age less than 60 years, no habitual alcohol intake, and Eastern Cooperative Oncology Group performance status (ECOG-PS) score of 1 were significant risk factors associated with non-CR. The findings of this study suggested the superiority of palonosetron to granisetron, without accompanying dexamethasone and aprepitant, for chemotherapy-induced nausea and vomiting in patients with malignant lymphoma..
9. Kensuke Sasaki, Yasuo Mori, Goichi Yoshimoto, Teppei Sakoda, Koji Kato, Kyoko Inadomi, Kenjiro Kamezaki, Katsuto Takenaka, Hiromi Iwasaki, Takahiro Maeda, Toshihiro Miyamoto, Koichi Akashi, Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation, Leukemia and Lymphoma, 10.1080/10428194.2017.1403021, 1-3, 2017.11.
10. Yasuo Mori, Goichi Yoshimoto, Jun Ichiro Yuda, Masayasu Hayashi, Jun Odawara, Takuro Kuriyama, Takeshi Sugio, Kohta Miyawaki, Kenjiro Kamezaki, Koji Kato, Katsuto Takenaka, Hiromi Iwasaki, Takahiro Maeda, Toshihiro Miyamoto, Koichi Akashi, Previous exposure to bortezomib is linked to a lower risk of engraftment syndrome after autologous hematopoietic stem cell transplantation, Leukemia and Lymphoma, 10.1080/10428194.2018.1466295, 1-3, 2018.05.
11. Kamezaki K, Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs, INTERNATIONAL JOURNAL OF HEMATOLOGY, 10.1007/s12185-016-2148-2, 105, 4, 423-432, 2017.04.
12. Kamezaki K, Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma, INTERNAL MEDICINE, 10.2169/internalmedicine.55.5987, 55, 13, 1793-1796, 2016.08.
13. Kamezaki K, Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 10.1016/j.bbmt.2016.05.017, 22, 9, 1608-1614, 2016.09.
14. Minami M, Shima T, Kato K, Yamamoto H, Tsuchihashi K, Oku S, Shimokawa T, Tochigi T, Yoshimoto G, Kamezaki K, Takenaka K, Iwasaki H, Oda Y, Miyamoto T, Akashi K, Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy., Int J Hematol, 2015.05.
15. Takashima S, Eto T, Shiratsuchi M, Hidaka M, Mori Y, Kato K, Kamezaki K, Oku S, Henzan H, Takase K, Matsushima T, Takenaka K, Iwasaki H, Miyamoto T, Akashi K, Teshima T, The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group., Intern Med, 2014.08.
16. Kamezaki K, Luchsinger LL, Snoeck HW, Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia, EXPERIMENTAL HEMATOLOGY, 10.1016/j.exphem.2013.11.008, 42, 3, 192-203, 2014.03.
17. Shima T, Miyamoto T, Kikushige Y, Mori Y, Kamezaki K, Takase K, Henzan H, Numata A, Ito Y, Takenaka K, Iwasaki H, Kamimura T, Eto T, Nagafuji K, Teshima T, Kato K, Akashi K, Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation, Blood, 10.1182/blood-2012-02-409607, 121, 5, 840-848, 2013.01.
18. Mori Y, Teshima T, Kamezaki K, Kato K, Takenaka K, Iwasaki H, Miyamoto T, Nagafuji K, Eto T, Akashi K, Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians, BONE MARROW TRANSPLANTATION, 10.1038/bmt.2011.229, 47, 8, 1075-1081, 2012.08.
19. Mori Y, Miyamoto T, Kamezaki K, Kato K, Kikushige Y, Takashima S, Urata S, Shimoda S, Shimono N, Takenaka K, Iwasaki H, Nagafuji K, Teshima T, Akashi K, Low incidence of adenovirus hemorrhagic cystitis following autologous hematopoietic stem cell transplantation in the rituximab era, AMERICAN JOURNAL OF HEMATOLOGY, 10.1002/ajh.23247, 87, 8, 828-830, 2012.08.
20. Mori Y, Miyamoto T, Kato K, Kamezaki K, Kuriyama T, Oku S, Takenaka K, Iwasaki H, Harada N, Shiratsuchi M, Abe Y, Nagafuji K, Teshima T, Akashi K, Different Risk Factors Related to Adenovirus- or BK Virus-Associated Hemorrhagic Cystitis following Allogeneic Stem Cell Transplantation, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 10.1016/j.bbmt.2011.07.025, 18, 3, 458-465, 2012.03.
21. Avagyan S, Aguilo F, Kamezaki K, Snoeck HW, Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor-beta 2 and FLT3 in hematopoiesis, Blood, 10.1182/blood-2011-07-365080, 118, 23, 6078-6086, 2011.12.
22. Aoki T, Miyamoto T, Mori Y, Yoshimoto G, Yamauchi T, Kamezaki K, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Shimono N, Teshima T, Akashi K, Successful allogeneic stem cell transplantation in two patients with acute myelogenous leukaemia and invasive aspergillosis by antifungal combination therapy, MYCOSES, 10.1111/j.1439-0507.2010.01858.x, 54, 4, E255-E259, 2011.07.
23. Mori Y, Miyamoto T, Nagafuji K, Kamezaki K, Yamamoto A, Saito N, Kato K, Takenaka K, Iwasaki H, Harada N, Abe Y, Teshima T, Akashi K, High Incidence of Human Herpes Virus 6-Associated Encephalitis/Myelitis following a Second Unrelated Cord Blood Transplantation, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 10.1016/j.bbmt.2010.05.009, 16, 11, 1596-1602, 2010.11.
24. Nishida R, Mori Y, Iwasaki H, Tokuyama T, Kamezaki K, Nagasaki Y, Oka H, Miyawaki K, Saito N, Takenaka K, Harada N, Miyamoto T, Teshima T, Akashi K, Pulmonary Nocardiosis Developed in a Hematopoietic Stem Cell Transplant Recipient with Bronchiolitis Obliterans, INTERNAL MEDICINE, 10.2169/internalmedicine.49.3658, 49, 14, 1441-1444, 2010.07.
25. Aoki T, Kamezaki K, Miyamoto T, Nagafuji K, Mori Y, Yamauchi T, Takenaka K, Iwasaki H, Harada N, Shimono N, Teshima T, Akashi K, Cord blood stem cell transplantation in a patient with disseminated mucormycosis and acute myelogenous leukemia, TRANSPLANT INFECTIOUS DISEASE, 10.1111/j.1399-3062.2010.00496.x, 12, 3, 277-279, 2010.06.
26. Mori Y, Nagasaki Y, Kamezaki K, Takenaka K, Iwasaki H, Harada N, Miyamoto T, Abe Y, Shimono N, Akashi K, Teshima T, High incidence of false-positive Aspergillus galactomannan test in multiple myeloma, AMERICAN JOURNAL OF HEMATOLOGY, 10.1002/ajh.21697, 85, 6, 449-451, 2010.06.
27. Numata A, Miyamoto T, Ohno Y, Kamimura T, Tanimoto T, Takase K, Henzan H, Kato K, Takenaka K, Fukuda T, Harada N, Nagafuji K, Teshima T, Akashi K, Harada M, Eto T, Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group, BONE MARROW TRANSPLANTATION, 10.1038/bmt.2009.165, 45, 2, 311-316, 2010.02.
28. Mori Y, Aoki T, Takenaka K, Yamauchi T, Yamamoto A, Kamezaki K, Iwasaki H, Harada N, Miyamoto T, Nagafuji K, Teshima T, Akashi K, Successful treatment of refractory advanced nasal NK/T cell lymphoma with unrelated cord blood stem cell transplantation incorporating focal irradiation, INTERNATIONAL JOURNAL OF HEMATOLOGY, 10.1007/s12185-009-0453-8, 91, 1, 107-111, 2010.01.
29. Takahara M, Tsuji G, Ishii N, Dainichi T, Hashimoto T, Kohno K, Kamezaki K, Nagafuji K, Takeuchi S, Moroi Y, Furue M, Mucous membrane pemphigoid with antibodies to the beta(3) subunit of Laminin 332 in a patient with acute myeloblastic leukemia and graft-versus-host disease., Dermatology, 219, 4, 361-4, 2009.10.
30. Yamauchi T, Mori Y, Miyamoto T, Kamezaki K, Aoki T, Yamamoto A, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Akashi K, Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia, INTERNATIONAL JOURNAL OF HEMATOLOGY, 10.1007/s12185-009-0405-3, 90, 3, 416-420, 2009.10.
31. Kohno K, Nagafuji K, Tsukamoto H, Horiuchi T, Takase K, Aoki K, Henzan H, Kamezaki K, Takenaka K, Miyamoto T, Teshima T, Harada M, Akashi K, Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases, TRANSPLANT INFECTIOUS DISEASE, 10.1111/j.1399-3062.2009.00401.x, 11, 4, 318-323, 2009.08.
32. Matsuo Y, Kamezaki K, Takeishi S, Takenaka K, Eto T, Nonami A, Miyamoto T, Iwasaki H, Harada N, Nagafuji K, Teshima T, Akashi K, Encephalomyelitis Mimicking Multiple Sclerosis Associated with Chronic Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation, INTERNAL MEDICINE, 10.2169/internalmedicine.48.2003, 48, 16, 1453-1456, 2009.08.
33. Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto G, Harada N, Yoshida M, Henzan H, Takase K, Miyamoto T, Akashi K, Harada M, Teshima T; Fukuoka Blood and Marrow Transplant Group (FBMTG). , Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients., Int J Hematol., 89(2):231-7., 2009.03.
34. Shima T, Yoshimoto G, Miyamoto T, Yoshida S, Kamezaki K, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Shimono N, Akashi K. , Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia., Transpl Infect Dis., 11(1):75-7., 2009.02.
35. Aoki T, Miyamoto T, Yoshida S, Yamamoto A, Yamauchi T, Yoshimoto G, Mori Y, Kamezaki K, Iwasaki H, Takenaka K, Harada N, Nagafuji K, Teshima T, Akashi K., Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9., Int J Hematol., 88(5):571-4. , 2008.10.
36. Shima T, Yoshimoto G, Nonami A, Yoshida S, Kamezaki K, Iwasaki H, Takenaka K, Miyamoto T, Harada N, Teshima T, Akashi K, Nagafuji K., Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient., Int J Hematol., 88(3):336-40., 2008.10.
37. Nonami A, Miyamoto T, Kuroiwa M, Kunisaki Y, Kamezaki K, Takenaka K, Harada N, Teshima T, Harada M, Nagafuji K., Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling., Jpn J Clin Oncol., 37(12):969-72., 2007.12.
38. Nonami A, Takenaka K, Sumida C, Aizawa K, Kamezaki K, Miyamoto T, Harada N, Nagafuji K, Teshima T, Harada M., Successful treatment of myelodysplastic syndrome (MDS)-related intestinal Behçet's disease by up-front cord blood transplantation., Intern Med., 46(20):1753-6., 2007.10.
39. Kamezaki K, Miyamoto T, Henzan T, Numata A, Iwasaki H, Nagafuji K, Harada M, Teshima T, Akashi K., Collection of mobilized peripheral blood stem cells from a donor with severe iron deficient anemia., J Clin Apher. , 22(5):292-294 , 2007.10.
40. Matsuo Y, Takeishi S, Miyamoto T, Nonami A, Kikushige Y, Kunisaki Y, Kamezaki K, Tu L, Hisaeda H, Takenaka K, Harada N, Kamimura T, Ohno Y, Eto T, Teshima T, Gondo H, Harada M, Nagafuji K., Toxoplasmosis encephalitis following severe graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation: 17 yr experience in Fukuoka BMT group., Eur J Haematol. , 79(4):317-21, 2007.10.
41. Kunisaki Y, Takase K, Miyamoto T, Fukata M, Nonami A, Kamezaki K, Kaji Y, Gondo H, Harada M, Nagafuji K., Marked improvement of cardiac function early after non-myeloablative BMT in a heavily transfused patient with severe aplastic anemia and heart failure., Bone Marrow Transplant., 40(6):593-5. , 2007.09.
42. Shimoda HK, Yamamoto M, Shide K, Kamezaki K, Matsuda T, Ogawa K, Harada M, Shimoda K., Chronic thrombopoietin overexpression induces mesangioproliferative glomerulopathy in mice., Am J Hematol. , 82(9):802-6. , 2007.09.
43. Kamezaki K, Kikushige Y, Numata A, Miyamoto T, Takase K, Henzan H, Aoki K, Kato K, Nonami A, Kamimura T, Arima F, Takenaka K, Harada N, Fukuda T, Hayashi S, Ohno Y, Eto T, Harada M, Nagafuji K., Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma., Bone Marrow Transplant. , 39(9):523-7. , 2007.05.
44. Shimoda K, Shide K, Kamezaki K, Okamura T, Harada N, Kinukawa N, Ohyashiki K, Niho Y, Mizoguchi H, Omine M, Ozawa K, Haradaa M., The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan., Int J Hematol. , 85(4):338-43. , 2007.05.
45. Nonami A, Takenaka K, Kamezaki K, Miyamoto T, Harada N, Nagafuji K, Teshima T, Harada M., Successful Treatment of Primary Cardiac Lymphoma by Rituximab-CHOP and High-Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation., Int J Hematol., 85(3):264-6. , 2007.04.
46. Nonami A, Takenaka K, Harada N, Kono K, Kamezaki K, Numata A, Karube K, Miyamoto T, Nagafuji K, Ohshima K, Harada M., Primary hepatic lymphoma 1 year after resection of hepatocellular carcinoma., J Clin Oncol., 24(36):5784-6., 2006.12.
47. Kikushige Y, Takase K, Miyamoto T, Numata A, Kamesaki K, Fukuda T, Nagafuji K, Gondo H, Harada M., Late relapse of acute myelogenous leukemia followed by epstein-barr virus-associated lymphoproliferative disease 11 years after allogeneic bone marrow transplantation., Int J Hematol., 84(5):441-4., 2006.12.
48. Shide K, Shimoda K, Kamezaki K, Kakumitsu H, Kumano T, Numata A, Ishikawa F, Takenaka K, Yamamoto K, Matsuda T, Harada M., Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence., Leuk Res, 28, 2006.08.
49. Imamura R, Miyamoto T, Yoshimoto G, Kamezaki K, Ishikawa F, Henzan H, Kato K, Takase K, Numata A, Nagafuji K, Okamura T, Sata M, Harada M, Inaba S., Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor., J Immunol., 175(4):2647-54., 2005.08.
50. Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, Numata A, Shide K, Matsuda T, Oshima K, Harada M., Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis., Leuk Res., 29(7):761-9, 2005.07.
51. Yokoyama T, Okamura S, Asano Y, Kamezaki K, Numata A, Kakumitsu H, Shide K, Nakashima H, Taisuke K, Sekine Y, Mizuno Y, Okamura J, Matsuda T, Harada M, Yoshiyuki N, Shimoda K., A novel mutation in the juxtamembrane intracellular sequence of the granulocyte colony-stimulating factor (G-CSF) receptor gene in a patient with severe congenital neutropenia augments GCSF proliferation activity but not through the MAP kinase cascade., Int J Hematol., 82(1):28-34., 2005.07.
52. Numata A, Shimoda K, Kamezaki K, Haro T, Kakumitsu H, Shide K, Kato K, Miyamoto T, Yamashita Y, Oshima Y, Nakajima H, Iwama A, Aoki K, Takase K, Gondo H, Mano H, Harada M., Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer-binding protein alpha in granulocyte colony-stimulating factor signaling pathway., J Biol Chem., 280(13):12621-9., 2005.04.
53. Tanimoto TE, Hirano A, Nagafuji K, Yamasaki S, Hashiguchi M, Okamura T, Kamezaki K, Takase K, Numata A, Miyamoto T, Fukuda T, Harada M., Mismatched unrelated cord blood transplantation in a patient with T-cell prolymphocytic leukemia., Leukemia., 19(4):679-81., 2005.04.
54. Kamezaki K, Fukuda T, Makino S, Harada M., Cyclophosphamide-induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation., Intern Med., 44(2):120-3., 2005.02.
55. Kamezaki K, Shimoda K, Numata A, Haro T, Kakumitsu H, Yoshie M, Yamamoto M, Takeda K, Matsuda T, Akira S, Ogawa K, Harada M., Roles of Stat3 and ERK in G-CSF Signaling., Stem Cells., 23(2):252-63., 2005.01.
56. Gondo H, Himeji D, Kamezaki K, Numata A, Tanimoto T, Takase K, Aoki K, Henzan H, Nagafuji K, Miyamoto T, Ishikawa F, Shimoda K, Inaba S, Tsukamoto H, Horiuchi T, Nakashima H, Otsuka T, Kato K, Kuroiwa M, Higuchi M, Shibuya T, Kamimura T, Kuzushima K, Tsur, Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation., Int J Hematol., 80(5):441-8., 2004.12.
57. Kamezaki K, Shimoda K, Numata A, Matsuda T, Nakayama K, Harada M., The role of Tyk2, Stat1 and Stat4 in LPS-induced endotoxin signals., Int Immunol., 16(8):1173-9., 2004.08.
58. Kamezaki K, Fukuda T, Makino S, Harada M., Evans' syndrome following autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma., Clin Lab Haematol., 26(4):291-3., 2004.08.
59. Haro T, Shimoda K, Kakumitsu H, Kamezaki K, Numata A, Ishikawa F, Sekine Y, Muromoto R, Matsuda T, Harada M., Tyrosine kinase 2 interacts with and phosphorylates receptor for activated C kinase-1, a WD motif-containing protein., J Immunol, 173(2):1151-7., 2004.07.
60. Aoki K, Shimoda K, Oritani K, Matsuda T, Kamezaki K, Muromoto R, Numata A, Tamiya S, Haro T, Ishikawa F, Takase K, Yamamoto T, Yumioka T, Miyamoto T, Nagafuji K, Gondo H, Nagafuchi S, Nakayama K, Harada M., Limitin, an interferon-like cytokine, transduces inhibitory signals on B-cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx., Exp Hematol., 31(12):1317-22., 2003.12.
61. Kamezaki K, Shimoda K, Numata A, Aoki K, Kato K, Takase K, Nakajima H, Ihara K, Haro T, Ishikawa F, Imamura R, Miyamoto T, Nagafuji K, Gondo H, Hara T, Harada M., The lipocalin 24p3, which is an essential molecule in IL-3 withdrawal-induced apoptosis, is not involved in the G-CSF withdrawal-induced apoptosis., Eur J Haematol., 71(6):412-7., 2003.12.
62. Kato K, Kamezaki K, Shimoda K, Numata A, Haro T, Aoki K, Ishikawa F, Takase K, Ariyama H, Matsuda T, Miyamoto T, Nagafuji K, Gondo H, Nakayama K, Harada M., Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth., Br J Haematol., 123(3):528-35., 2003.11.
63. Shimoda K, Kamesaki K, Numata A, Aoki K, Matsuda T, Oritani K, Tamiya S, Kato K, Takase K, Imamura R, Yamamoto T, Miyamoto T, Nagafuji K, Gondo H, Nagafuchi S, Nakayama K, Harada M., Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation., J Immunol., 169(9):4707-11., 2002.11.
64. Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, Aoki K, Kato K, Nagafuji K, Shimoda K, Okamura T, Kinukawa N, Kasuga N, Sata M, Harada M., Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction., Bone Marrow Transplant., 29(7):599-606., 2002.04.